drugset / Trial / NCT05660954
Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.
Phase 2
Completed
41 enrolled
Spanish Group for Research in Neuroendocrine Tumors
Ipsen · collabMFAR · collab
NaSingle-groupOpen-labelTreatment
Summary
CABOTHYROID is a prospective, exploratory, biomarker-focused, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study of cabozantinib in patients with previously treated advanced radioactive-iodine refractory
Timeline
- Start
- 2023-05-25
- Primary completion
- 2025-11-30
- Completion
- 2025-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | 60 mg | Oral |